Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study

BACKGROUND: The phase 3 randomized PERSIST study demonstrated the efficacy and tolerability of galcanezumab, a humanized anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for prevention of episodic migraines. We present findings from the open-label extension (OLE) of PERSIST, which eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jiying, Zhong, Lianmei, Chowdhury, Debashish, Skorobogatykh, Kirill, Luo, Guogang, Yang, Xiaosu, Zhang, Mingjie, Sun, Lingli, Liu, Hui, Qian, Chenxi, Yu, Shengyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401806/
https://www.ncbi.nlm.nih.gov/pubmed/37542222
http://dx.doi.org/10.1186/s10194-023-01613-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401806/
https://www.ncbi.nlm.nih.gov/pubmed/37542222
http://dx.doi.org/10.1186/s10194-023-01613-1

Ejemplares similares